中国癌症防治杂志Issue(3)：213-217,218,6.DOI:10.3969/j.issn.1674-5671.2015.03.16
索拉非尼治疗晚期原发性肝癌的疗效和影响因素分析
Factors affecting efficacy and safety of sorafenib for advanced primary liver cancer
朱丽君 1王莉 2韦明景 1蓝肖玲 2黄露 1刘志辉 2梁嵘 1林燕 2廖思娜 1原春玲 2黎倩 1张玉梅 1廖小莉 1李永强1
作者信息
- 1. 530021 南宁 广西医科大学附属肿瘤医院化疗一科
- 2. 广西医科大学研究生学院
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of sorafenib in the treatment of advanced primary liver cancer and analyze factors that may affect drug outcomes. Methods Medical records of 78 patients with advanced primary liver cancer who received sorafenib from January 2008 to September 2013 were analyzed. Logistic regression was used to identify variables influencing response rate and disease control rate. Overall survival and progression-free survival were estimated using the Kaplan-Meier method,and Cox proportional hazard multivariate modeling was used to identify prognostic factors. Results Median follow-up time for the 78 patients was 192 days (95%CI 173-218). No complete remission or partial remission was observed,and stable disease occurred in 48 patients (61.5%),corresponding to a disease control rate of 61.5%. Disease progression occurred in 30 patients. Median overall survival was 196 days(95%CI 173-218)and median progression-free survival was 96 days(95%CI 93-98). Multivariate analysis identified age and HBV infection as independent risk factors for disease control rate. Child-Pugh class and previous chemotherapy were identified as independent prognostic factors of overall and progression-free survival. ECOG performance status was also found to be an independent predictor of overall survival. Most adverse events were grade 1 or 2. Two patients experienced grade IV hand-foot syndrome. No treatment-related deaths were recorded. Conclusion Sorafenib shows substantial survival benefit and tolerable toxicity in patients with advanced primary liver cancer. Lower ECOG performance status,Child-Pugh A class and previous chemotherapy predict better survival.关键词
原发性肝癌/索拉非尼/化疗/疗效/影响因素Key words
Liver neoplasm/Sorafenib/Chemotherapy/Efficacy/Prognostic factors分类
医药卫生引用本文复制引用
朱丽君,王莉,韦明景,蓝肖玲,黄露,刘志辉,梁嵘,林燕,廖思娜,原春玲,黎倩,张玉梅,廖小莉,李永强..索拉非尼治疗晚期原发性肝癌的疗效和影响因素分析[J].中国癌症防治杂志,2015,(3):213-217,218,6.
